Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA (2022)
Sequence: cyclo-(Asp-Pro-Asp-Pro-Asp-Pro)
| Experiment Id | EXP000189 |
|---|---|
| Paper | Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA |
| Peptide | cyclo-(DP)3 / (CP)6NS |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | Covalently assembled cyclic-peptide nanospheres (CP6NS) |
| Formulation Components | ~90 nm |
| Size Nm | |
| Zeta Mv | 17.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-231 breast cancer cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown + apoptosis |
| Output Value | ~42% survivin mRNA knockdown; increased apoptosis |
| Output Units | |
| Output Notes | Comparable silencing to Lipofectamine 2000; low toxicity |
| Toxicity Notes | |
| Curation Notes |